image001-1

ꯄ꯭ꯔꯗꯛꯇ ꯗꯤꯁ꯭ꯛꯔꯤꯄꯁꯟ꯫

ꯚꯦꯂꯦꯔꯤꯌꯥꯅꯥ ꯑꯣꯐꯤꯁꯤꯅꯥꯂꯤꯁ ꯑꯦꯜ.ꯒꯤ ꯁꯨꯡꯕꯥ ꯃꯔꯨ ꯑꯃꯁꯨꯡ ꯔꯥꯏꯖꯣꯃꯁꯤꯡꯗꯒꯤ ꯏꯊꯥꯅꯣꯜ ꯔꯤꯐ꯭ꯂꯛꯁ ꯑꯦꯛꯁꯠꯔꯥꯛꯁꯟ, ꯃꯦꯛꯔꯣꯄꯣꯔꯣꯁ ꯔꯦꯁꯤꯟ ꯁꯨꯡꯗꯣꯀꯄꯥ, ꯑꯃꯁꯨꯡ ꯂꯣ-ꯇꯦꯝꯄꯦꯔꯦꯆꯔꯗꯥ ꯚꯦꯛꯌꯨꯝ ꯁꯨꯡꯕꯥ ꯁꯤꯖꯤꯟꯅꯗꯨꯅꯥ ꯁꯦꯃꯈꯤꯕꯅꯤ꯫ ꯄꯨꯊꯣꯀꯄꯥ ꯑꯁꯤ ꯖꯤ.ꯑꯦꯝ.ꯄꯤ.ꯒꯤ ꯁ꯭ꯇꯦꯟꯗꯔꯗꯁꯤꯡ ꯑꯀꯅꯕꯥ ꯃꯑꯣꯡꯗꯥ ꯉꯥꯛꯅꯥ ꯆꯠꯂꯤ꯫ ꯑꯦꯛꯁꯠꯔꯥꯛꯁꯟ ꯇꯦꯝꯄꯦꯔꯦꯆꯔ ꯑꯁꯤ ꯍꯤꯠ-ꯁꯦꯟꯁꯤꯇꯤꯚ ꯑꯦꯛꯇꯤꯕ ꯀꯝꯄꯣꯅꯦꯟꯇꯁꯤꯡ (ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯚꯦꯂꯦꯔꯦꯅꯤꯛ ꯑꯦꯁꯤꯗ) ꯁꯣꯀꯍꯟꯗꯅꯕꯥ ꯗꯤꯒ꯭ꯔꯤ 50–60ꯗꯥ ꯀꯟꯠꯔꯣꯜ ꯇꯧꯏ, ꯃꯁꯤꯅꯥ ꯑꯦꯛꯇꯤꯕ ꯏꯅꯒ꯭ꯔꯦꯗꯤꯌꯦꯟꯇꯁꯤꯡꯒꯤ 90%ꯗꯒꯤ ꯍꯦꯟꯅꯥ ꯅꯠꯠꯔꯒꯥ ꯃꯁꯤꯒꯥ ꯃꯥꯟꯅꯕꯥ ꯔꯤꯇꯦꯟꯁꯟ ꯁꯣꯌꯗꯅꯥ ꯂꯩꯍꯜꯂꯤ꯫ ꯏꯊꯥꯅꯣꯂꯒꯤ ꯔꯦꯁꯤꯗꯦꯟꯇ ꯑꯁꯤ...<0.5%, meeting food and pharmaceutical-grade requirements.

ꯃꯔꯨꯑꯣꯏꯕꯥ ꯑꯦꯛꯇꯤꯕ ꯀꯝꯄꯣꯅꯦꯟꯇꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯐꯉ꯭ꯀꯁꯅꯁꯤꯡ꯫

ꯚꯦꯂꯦꯔꯦꯅꯤꯛ ꯑꯦꯁꯤꯗ: ꯱.ꯄ꯭ꯔꯥꯏꯃꯥꯔꯤ ꯁꯦꯗꯦꯇꯤꯚ ꯀꯝꯄꯣꯅꯦꯟꯇ ꯑꯗꯨ; ꯁꯦꯟꯠꯔꯦꯜ ꯅꯔꯚꯁ ꯁꯤꯁ꯭ꯇꯦꯃꯗꯥ ꯂꯩꯕꯥ ꯖꯤ.ꯑꯦ.ꯕꯤ.ꯑꯦ.

ꯚꯦꯂꯦꯔꯥꯅꯣꯟ: ꯱.ꯑꯦꯟꯇꯤ-ꯏꯅꯐ꯭ꯂꯦꯃꯦꯇꯔꯤ ꯑꯃꯁꯨꯡ ꯑꯦꯅꯥꯂꯖꯦꯁꯤꯛ ꯄ꯭ꯔꯣꯄꯔꯇꯤꯁꯤꯡ ꯎꯠꯂꯤ, ꯃꯁꯤꯅꯥ ꯃꯁꯜ ꯇꯦꯟꯁꯟ ꯑꯃꯁꯨꯡ ꯍꯦꯗ-ꯑꯦꯛ ꯂꯥꯀꯁꯤꯅꯕꯗꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯏ, ꯚꯦꯂꯦꯔꯦꯅꯤꯛ ꯑꯦꯁꯤꯗꯀꯥ ꯂꯣꯌꯅꯅꯥ ꯁꯤꯅꯦꯔꯖꯤꯁ꯭ꯇꯤꯛ ꯑꯣꯏꯅꯥ ꯊꯋꯥꯏ ꯌꯥꯑꯣꯕꯥ ꯏꯐꯦꯛꯇꯁꯤꯡ ꯍꯦꯅꯒꯠꯍꯜꯂꯤ꯫

ꯐ꯭ꯂꯦꯕꯣꯅꯣꯏꯗꯁꯤꯡ (ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯀ꯭ꯌꯨꯔꯁꯦꯇꯤꯟ, ꯀꯦꯃꯐꯦꯔꯣꯜ):ꯑꯦꯟꯇꯤꯑꯣꯛꯁꯤꯗꯦꯟꯇ ꯑꯦꯛꯇꯤꯚꯤꯇꯤꯅꯥ ꯐ꯭ꯔꯤ ꯔꯦꯗꯤꯀꯦꯂꯁꯤꯡ ꯁ꯭ꯀꯦꯚꯦꯟꯖ ꯇꯧꯕꯗꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯏ, ꯅꯔꯚ ꯁꯦꯂꯁꯤꯡꯗꯥ ꯑꯣꯛꯁꯤꯗꯦꯇꯤꯕ ꯑꯣꯏꯕꯥ ꯑꯃꯥꯡ-ꯑꯇꯥ ꯍꯟꯊꯍꯜꯂꯤ ꯑꯃꯁꯨꯡ ꯅꯔꯚ ꯁꯤꯁ꯭ꯇꯦꯝ ꯉꯥꯀꯊꯣꯀꯄꯗꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯏ꯫

ꯄꯣꯠꯊꯣꯛꯀꯤ ꯀꯥꯟꯅꯕꯥ꯫

ꯀ꯭ꯂꯤꯌꯥꯔ ꯀꯣꯔ ꯏꯐꯤꯁꯤꯑꯦꯟꯁꯤ – ꯃꯔꯨꯑꯣꯏꯕꯥ ꯁꯦꯗꯦꯇꯤꯚ ꯑꯃꯁꯨꯡ ꯔꯤꯂꯥꯛꯁꯦꯁꯟ ꯏꯐꯦꯛꯇꯁꯤꯡ꯫

ꯁ꯭ꯂꯤꯞ ꯑꯦꯗ: ꯱.ꯀ꯭ꯂꯤꯅꯤꯀꯦꯜ ꯁ꯭ꯇꯗꯤꯁꯤꯡꯅꯥ ꯇꯥꯛꯂꯤ ꯃꯗꯨꯗꯤ ꯚꯦꯂꯦꯔꯤꯌꯥꯟ ꯑꯦꯛꯁꯠꯔꯦꯛꯇ (ꯚꯦꯂꯦꯔꯤꯌꯟ ꯑꯦꯁꯤꯗ 0.8%ꯗꯒꯤ ꯍꯦꯟꯅꯥ ꯅꯠꯠꯔꯒꯥ ꯃꯁꯤꯒꯥ ꯃꯥꯟꯅꯕꯥ) ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ/ꯅꯨꯃꯤꯠ 300–600ꯅꯥ ꯆꯥꯡꯆꯠꯇꯥ ꯇꯨꯝꯕꯥ ꯍꯧꯕꯒꯤ ꯃꯇꯝ ꯑꯁꯤ ꯃꯤꯅꯠ 20–30 ꯍꯟꯊꯍꯅꯕꯥ ꯉꯝꯃꯤ ꯑꯃꯁꯨꯡ ꯌꯥꯝꯅꯥ ꯂꯨꯅꯥ ꯇꯨꯝꯕꯥ ꯃꯇꯝ ꯍꯦꯅꯒꯠꯍꯅꯕꯥ ꯉꯝꯃꯤ꯫ ꯃꯇꯝ ꯃꯇꯃꯒꯤ ꯑꯣꯏꯅꯥ ꯇꯨꯝꯕꯥ ꯌꯥꯗꯕꯒꯤ ꯏꯐꯦꯛꯇꯤꯚ ꯔꯦꯠ ꯑꯁꯤ 80% ꯍꯦꯜꯂꯤ꯫

ꯑꯦꯟꯇꯤ-ꯑꯦꯅꯖꯥꯏꯇꯤ ꯑꯃꯁꯨꯡ ꯀꯂꯃꯤꯡ:ꯃꯊꯪꯒꯤ-ꯅꯨꯃꯤꯠꯀꯤ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯇꯨꯝꯕꯥ ꯌꯥꯗꯅꯥ ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥꯗꯒꯤ ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥ ꯋꯥꯈꯜ ꯅꯨꯡꯉꯥꯏꯇꯕꯥ (ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯁ꯭ꯠꯔꯦꯁ-ꯏꯅꯗ꯭ꯌꯨꯁ ꯇꯧꯔꯕꯥ ꯇꯦꯟꯁꯟ, ꯏꯔꯤꯇꯦꯕꯤꯂꯤꯇꯤ) ꯂꯥꯀꯁꯤꯟꯅꯕꯥ ꯁꯦꯟꯠꯔꯦꯜ ꯅ꯭ꯌꯨꯔꯣꯠꯔꯥꯟꯁꯃꯤꯇꯔꯁꯤꯡ ꯃꯣꯗ꯭ꯌꯨꯜ ꯇꯧꯏ꯫ ꯕꯦꯟꯖꯣꯗꯤꯌꯥꯖꯦꯄꯤꯅꯁꯤꯡꯒꯥ ꯆꯥꯡꯗꯝꯅꯕꯗꯥ ꯍꯦꯟꯅꯥ ꯁꯥꯐꯕꯥ꯫

ꯃꯁꯜ ꯔꯤꯂꯦꯛꯁꯟ ꯇꯧꯕꯥ: ꯱.ꯇꯣꯄꯤꯀꯦꯜ ꯅꯠꯠꯔꯒꯥ ꯑꯣꯔꯦꯜ ꯑꯦꯗꯃꯤꯅꯤꯁ꯭ꯠꯔꯦꯁꯟꯅꯥ ꯃꯁꯜ ꯁꯣꯟꯊꯕꯥ ꯑꯃꯁꯨꯡ ꯇꯦꯟꯁꯟ ꯍꯦꯗ-ꯑꯦꯀꯁꯤꯡ ꯀꯣꯀꯍꯅꯕꯥ ꯉꯝꯃꯤ; ꯏꯟ ꯚꯤꯠꯔꯣ ꯁ꯭ꯇꯗꯤꯁꯤꯡꯅꯥ ꯇꯥꯛꯂꯤ ꯃꯗꯨꯗꯤ 100 ug/mLꯅꯥ ꯁ꯭ꯃꯨꯗ ꯃꯁꯜ ꯀꯟꯠꯔꯦꯀꯁꯟ ꯐ꯭ꯔꯤꯛꯕꯦꯟꯁꯤ 30% ꯍꯟꯊꯍꯜꯂꯤ꯫

ꯍꯥꯏ ꯁꯦꯐꯇꯤ ꯄ꯭ꯔꯣꯐꯥꯏꯜ – ꯌꯨꯖꯔꯁꯤꯡꯒꯤ ꯄꯥꯛ-ꯆꯥꯎꯔꯕꯥ ꯔꯦꯟꯖ ꯑꯃꯒꯤꯗꯃꯛ ꯆꯨꯅꯕꯥ꯫
ꯏ.ꯁꯤ.ꯑꯣ.ꯁꯤ.ꯏ.ꯑꯥꯔ.ꯇꯤ.ꯑꯣꯔꯒꯥꯅꯤꯛ (ꯏ.ꯌꯨ.), ꯌꯨ.ꯑꯦꯁ.ꯗꯤ.ꯑꯦ.ꯒꯤ ꯑꯣꯔꯒꯥꯅꯤꯛ, ꯀꯣꯁꯔ, ꯑꯃꯁꯨꯡ ꯍꯂꯥꯜ ꯌꯥꯑꯣꯅꯥ ꯏꯟꯇꯔꯅꯦꯁ꯭ꯅꯦꯜ ꯁꯔꯇꯤꯐꯤꯀꯦꯁꯅꯁꯤꯡ ꯉꯥꯛꯅꯥ ꯆꯠꯂꯤ꯫ ꯑꯍꯂꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯆꯍꯤ ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥ-ꯆꯍꯤ/ꯑꯍꯜ ꯑꯣꯏꯔꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯒꯤꯗꯃꯛ ꯆꯨꯅꯕꯥ (ꯃꯤꯔꯣꯜꯂꯤꯕꯤ ꯅꯠꯠꯔꯒꯥ ꯈꯣꯝꯂꯥꯡ ꯄꯤꯊꯀꯄꯥ ꯅꯨꯄꯤꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯆꯍꯤ 12ꯒꯤ ꯃꯈꯥꯗꯥ ꯂꯩꯕꯥ ꯑꯉꯥꯡꯁꯤꯡ ꯅꯠꯇꯅꯥ, ꯍꯦꯂꯊꯀꯦꯌꯔ ꯄ꯭ꯔꯣꯐꯦꯁꯅꯦꯜ ꯑꯃꯅꯥ ꯄꯥꯎꯇꯥꯛ ꯄꯤꯗ꯭ꯔꯤꯐꯥꯎꯕꯥ)꯫

ꯑꯦꯞꯂꯤꯀꯦꯁꯅꯁꯤꯡ ꯄꯤꯕꯥ꯫

ꯐꯥꯔꯃꯥꯁ꯭ꯌꯨꯇꯤꯀꯦꯜ ꯑꯃꯁꯨꯡ ꯍꯦꯜꯊꯀꯦꯌꯔ꯫

ꯁ꯭ꯂꯤꯞ ꯑꯦꯗ ꯍꯤꯗꯥꯀꯁꯤꯡ: ꯱.ꯃꯇꯝ ꯃꯇꯃꯒꯤ ꯑꯣꯏꯅꯥ ꯇꯨꯝꯕꯥ ꯉꯃꯗꯕꯥ ꯑꯃꯁꯨꯡ ꯅ꯭ꯌꯨꯔꯥꯁ꯭ꯇꯦꯅꯤꯌꯥ-ꯒꯥ ꯃꯔꯤ ꯂꯩꯅꯕꯥ ꯇꯨꯝꯕꯥ ꯌꯥꯗꯕꯥ ꯗꯤꯁꯑꯣꯔꯗꯔꯁꯤꯡꯒꯤꯗꯃꯛ ꯚꯦꯂꯦꯔꯤꯌꯥꯟ ꯇꯦꯕ꯭ꯂꯦꯠ ꯅꯠꯠꯔꯒꯥ ꯀꯦꯄꯁꯨꯂꯁꯤꯡ꯫ ꯀ꯭ꯂꯤꯅꯤꯀꯦꯜ ꯗꯦꯇꯥꯅꯥ "ꯇꯨꯝꯕꯥ ꯉꯃꯗꯕꯥ" ꯃꯈꯂꯒꯤ ꯏꯅꯁꯣꯃꯅꯤꯌꯥ (85% ꯐꯥꯎꯕꯥ)ꯗꯥ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯋꯥꯡꯕꯥ ꯏꯐꯤꯁꯤꯑꯦꯟꯁꯤ ꯎꯠꯂꯤ꯫

ꯑꯦꯟꯇꯤ-ꯑꯦꯅꯖꯥꯏꯇꯤ ꯐꯣꯔꯃꯨꯂꯦꯁꯅꯁꯤꯡ:ꯁꯦꯟꯇ ꯖꯣꯅꯁ ꯋꯔꯠ ꯅꯠꯠꯔꯒꯥ ꯄꯦꯁꯅꯐ꯭ꯂꯥꯋꯥꯔ ꯑꯦꯛꯁꯠꯔꯦꯛꯇꯁꯤꯡꯒꯥ ꯄꯨꯅꯁꯤꯟꯅꯗꯨꯅꯥ ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥꯗꯒꯤ ꯃꯌꯥꯌ ꯑꯣꯏꯕꯥ ꯋꯥꯈꯜ ꯋꯥꯕꯥ ꯂꯥꯌꯦꯡꯕꯗꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯗꯨꯅꯥ ꯍꯤꯗꯥꯛ ꯑꯃꯈꯛꯇꯗꯥ ꯊꯥꯖꯕꯥ ꯊꯝꯕꯥ ꯍꯟꯊꯍꯜꯂꯤ꯫

ꯑꯦꯅꯥꯂꯖꯦꯁꯤꯛ ꯑꯃꯁꯨꯡ ꯔꯤꯂꯥꯛꯁꯦꯁꯟ ꯍꯤꯗꯥꯀꯁꯤꯡ:ꯃꯁꯜ ꯁꯣꯟꯊꯕꯥ ꯅꯠꯠꯔꯒꯥ ꯁꯔꯨ ꯇꯥꯡꯒꯤ ꯑꯅꯥꯕꯒꯤꯗꯃꯛ ꯇꯣꯄꯤꯀꯦꯜ ꯖꯦꯂꯁꯤꯡ (ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯔꯤꯌꯨꯃꯦꯇꯣꯏꯗ ꯑꯔꯊ꯭ꯔꯥꯏꯇꯤꯁ), ꯇꯦꯟꯁꯟ ꯍꯦꯗ-ꯑꯦꯀꯁꯤꯡꯒꯤꯗꯃꯛꯇꯥ ꯑꯣꯔꯦꯜ ꯄ꯭ꯔꯦꯄꯥꯔꯦꯁꯅꯁꯤꯡ꯫

ꯗꯥꯏꯑꯦꯇꯔꯤ ꯁꯞꯂꯤꯃꯦꯟꯇꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯍꯀꯁꯦꯂꯒꯤ ꯄꯣꯠꯊꯣꯀꯁꯤꯡ꯫

ꯁ꯭ꯂꯤꯞ ꯁꯄꯣꯔꯠ ꯄ꯭ꯔꯗꯛꯇꯁꯤꯡ: ꯱.ꯃꯍꯧꯁꯥꯅꯥ 5–10%ꯒꯤ ꯆꯥꯡꯗꯥ (0.8%ꯗꯒꯤ ꯍꯦꯟꯅꯥ ꯅꯠꯠꯔꯒꯥ ꯃꯁꯤꯒꯥ ꯃꯥꯟꯅꯕꯥ ꯚꯦꯂꯦꯔꯤꯌꯟ ꯑꯦꯁꯤꯗ ꯌꯥꯎꯕꯥ ꯑꯦꯛꯁꯠꯔꯦꯛꯇꯇꯥ ꯌꯨꯝꯐꯝ ꯑꯣꯏꯕꯥ, ꯁ꯭ꯠꯔꯦꯁ ꯂꯩꯕꯥ ꯅꯠꯠꯔꯒꯥ ꯇꯨꯝꯕꯥ ꯌꯥꯗꯕꯒꯤ ꯃꯒꯨꯟ ꯂꯩꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯅꯥ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯁꯤꯖꯤꯟꯅꯕꯗꯥ ꯆꯨꯅꯕꯥ ꯚꯦꯂꯦꯔꯤꯌꯥꯟ ꯒꯝ ꯅꯠꯠꯔꯒꯥ ꯁꯣꯂꯤꯗ ꯊꯛꯅꯕꯁꯤꯡ꯫

ꯁ꯭ꯠꯔꯦꯁ-ꯔꯤꯂꯤꯐ ꯄ꯭ꯔꯗꯛꯇꯁꯤꯡ:ꯃꯦꯂꯥꯇꯣꯅꯤꯟ ꯅꯠꯠꯔꯒꯥ GABAꯒꯥ ꯂꯣꯌꯅꯅꯥ "ꯄ꯭ꯔꯤ-ꯇꯨꯝꯕꯥ ꯀꯂꯃꯤꯡ ꯑꯣꯔꯦꯜ ꯂꯤꯛꯌꯨꯏꯗꯁꯤꯡ ꯁꯦꯃꯒꯠꯅꯕꯥ, ꯃꯊꯪꯒꯤ-ꯅꯨꯃꯤꯠꯀꯤ ꯇꯨꯝꯕꯥ ꯌꯥꯗꯅꯥ ꯇꯨꯝꯕꯥ ꯑꯃꯁꯨꯡ ꯋꯥꯈꯜ ꯔꯤꯒꯨꯂꯦꯁꯟ ꯄ꯭ꯔꯣꯃꯣꯠ ꯇꯧꯕꯥ꯫

ꯃꯤꯗꯜ-ꯆꯍꯤ/ꯑꯍꯜ ꯑꯣꯏꯔꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯒꯤ ꯍꯀꯁꯦꯜ:ꯅꯔꯚꯁ ꯁꯤꯁ꯭ꯇꯦꯝ ꯑꯁꯤ ꯍꯦꯟꯅꯥ-ꯅꯥ ꯁꯣꯀꯍꯟꯗꯅꯥ ꯇꯨꯝꯕꯥ ꯌꯥꯗꯕꯒꯤ ꯃꯒꯨꯟ ꯇꯞꯅꯥ ꯇꯞꯅꯥ ꯐꯒꯠꯍꯟꯅꯕꯥ ꯂꯣ-ꯗꯣꯖ ꯚꯦꯂꯦꯔꯤꯌꯥꯟ ꯀꯦꯄꯁꯨꯂꯁꯤꯡ (200 mg/day)꯫

ꯀꯁꯃꯦꯇꯤꯛꯁ ꯑꯃꯁꯨꯡ ꯄꯔꯁꯣꯅꯦꯜ ꯀꯦꯌꯔ꯫

ꯅꯨꯡꯉꯥꯏꯍꯅꯕꯥ ꯁ꯭ꯀꯤꯅꯀꯦꯌꯔ ꯄ꯭ꯔꯗꯛꯇꯁꯤꯡ:꯰.꯵–꯲%ꯗꯥ ꯅꯥꯏꯇꯣꯝ ꯔꯤꯄꯦꯌꯥꯔ ꯃꯥꯁ꯭ꯛ ꯅꯠꯠꯔꯒꯥ ꯀꯂꯃꯤꯡ ꯕꯣꯗꯤ ꯂꯣꯁꯅꯁꯤꯡꯗꯥ ꯍꯥꯄꯆꯤꯜꯂꯤ, ꯃꯁꯤꯅꯥ ꯇꯣꯄꯤꯀꯦꯜ ꯑꯦꯕꯁꯣꯔꯄꯁꯟ ꯑꯃꯁꯨꯡ ꯁꯦꯟꯇꯒꯤ ꯈꯨꯠꯊꯥꯡꯗꯥ ꯁ꯭ꯀꯤꯟ ꯁ꯭ꯠꯔꯦꯁ ꯔꯤꯂꯤꯐ (ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯂꯥꯂꯍꯧꯕꯥ, ꯁꯣꯀꯄꯥ, ꯇꯞꯅꯥ ꯇꯞꯅꯥ ꯁꯣꯀꯄꯥ) ꯄꯤ꯫

ꯑꯦꯔꯣꯃꯥꯊꯦꯔꯥꯄꯤꯒꯤ ꯄꯣꯠꯊꯣꯀꯁꯤꯡ: ꯱.ꯑꯣꯂꯐꯦꯛꯇꯔꯤ ꯄꯥꯊꯁꯤꯡꯒꯤ ꯈꯨꯠꯊꯥꯡꯗꯥ ꯋꯥꯈꯜ ꯅꯨꯡꯉꯥꯏꯅꯥ ꯂꯩꯅꯕꯥ ꯑꯃꯁꯨꯡ ꯇꯨꯝꯕꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯅꯕꯥ ꯗꯤꯐ꯭ꯌꯨꯁꯔ ꯅꯠꯠꯔꯒꯥ ꯁ꯭ꯂꯤꯞ ꯁ꯭ꯞꯔꯦꯁꯤꯡꯒꯤꯗꯃꯛꯇꯥ ꯚꯦꯂꯦꯔꯤꯌꯥꯟ ꯏꯁꯦꯟꯁꯤꯑꯦꯜ ꯑꯣꯏꯜ ꯑꯦꯛꯁꯠꯔꯦꯛꯇ (ꯂꯦꯚꯦꯟꯗꯔ ꯅꯠꯠꯔꯒꯥ ꯀꯦꯃꯣꯃꯤꯂꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯕ꯭ꯂꯦꯟꯗ ꯇꯧꯕꯥ)꯫

ꯑꯣꯔꯦꯜ ꯀꯦꯌꯔ: ꯱.ꯑꯣꯔꯦꯜ ꯃ꯭ꯌꯨꯀꯣꯁꯥ ꯇꯦꯟꯁꯟ ꯑꯃꯁꯨꯡ ꯏꯅꯐ꯭ꯂꯦꯃꯦꯁꯟ ꯂꯥꯀꯁꯤꯟꯅꯕꯥ ꯅꯨꯡꯉꯥꯏꯍꯅꯕꯥ ꯌꯥꯕꯥ ꯃꯥꯎꯊꯋꯥꯁ (0.3–0.5%)ꯗꯥ ꯍꯥꯄꯆꯤꯜꯂꯤ, ꯃꯁꯤꯅꯥ ꯅꯨꯡꯉꯥꯏꯇꯕꯥ ꯃꯁꯛ ꯑꯗꯨ ꯃꯦꯟꯇꯣꯂꯅꯥ ꯃꯥꯁ꯭ꯛ ꯇꯧꯏ꯫

ꯐꯤꯗ ꯑꯃꯁꯨꯡ ꯄꯦꯠ ꯄ꯭ꯔꯗꯛꯇꯁꯤꯡ꯫

ꯄꯦꯠ ꯍꯦꯜꯊ: ꯱.ꯑꯀꯣꯌꯔꯣꯅꯒꯤ ꯑꯍꯣꯡꯕꯥ (ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯔꯤꯂꯣꯀꯦꯁꯟ, ꯇ꯭ꯔꯥꯟꯁꯄꯣꯔꯇꯦꯁꯟ)ꯅꯥ ꯊꯣꯀꯍꯅꯕꯥ ꯋꯥꯈꯜ ꯅꯨꯡꯉꯥꯏꯇꯕꯥ ꯅꯠꯠꯔꯒꯥ ꯁ꯭ꯠꯔꯦꯁ ꯍꯟꯊꯍꯟꯅꯕꯥ 0.2–0.5%ꯗꯥ ꯌꯨꯃꯁꯥ ꯑꯃꯁꯨꯡ ꯀꯦꯇꯁꯤꯡꯒꯤꯗꯃꯛꯇꯥ "ꯑꯦꯟꯇꯤ-ꯁ꯭ꯠꯔꯦꯁ ꯐꯤꯗ ꯑꯦꯗꯤꯇꯤꯚ" ꯑꯃꯥ ꯑꯣꯏꯅꯥ ꯁꯤꯖꯤꯟꯅꯩ꯫

ꯇꯦꯛꯅꯤꯀꯦꯜ ꯁꯄꯣꯔꯠ & ꯀꯁ꯭ꯇꯃꯔꯥꯏꯖꯦꯁꯟ ꯇꯧꯕꯥ꯫

ꯐꯪꯒꯗꯕꯥ ꯁꯔꯇꯤꯐꯤꯀꯦꯇꯁꯤꯡ:ꯁꯤ.ꯑꯣ.ꯑꯦ.(ꯁꯔꯇꯤꯐꯤꯀꯦꯠ ꯑꯣꯐ ꯑꯦꯅꯥꯂꯥꯏꯁꯤꯁ), ꯑꯦꯝ.ꯑꯦꯁ.ꯗꯤ.ꯑꯦꯁ.(ꯃꯦꯇꯔꯤꯑꯦꯜ ꯁꯦꯐꯇꯤ ꯗꯦꯇꯥ ꯁꯤꯠ), ꯑꯣꯔꯒꯥꯅꯤꯛ ꯁꯔꯇꯤꯐꯤꯀꯦꯠꯁꯤꯡ (ꯌꯨ.ꯑꯦꯁ.ꯗꯤ.ꯑꯦ./ꯑꯦꯟ.ꯑꯣ.ꯄꯤ.)꯫

ꯆꯦꯀꯁꯤꯟ ꯊꯧꯔꯥꯡ ꯂꯧꯈꯠꯀꯗꯕꯅꯤ꯫

ꯃꯤꯔꯣꯜꯂꯤꯕꯤ ꯅꯠꯠꯔꯒꯥ ꯈꯣꯝꯂꯥꯡ ꯄꯤꯊꯛꯂꯤꯕꯥ ꯅꯨꯄꯤꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯆꯍꯤ 12ꯒꯤ ꯃꯈꯥꯗꯥ ꯂꯩꯕꯥ ꯑꯉꯥꯡꯁꯤꯡꯅꯥ ꯄ꯭ꯔꯣꯐꯦꯁꯅꯦꯜ ꯒꯥꯏꯗꯂꯥꯏꯅꯁꯤꯡꯒꯤ ꯃꯈꯥꯗꯥ ꯁꯤꯖꯤꯟꯅꯒꯗꯕꯅꯤ꯫

ꯌꯨ ꯑꯃꯁꯨꯡ ꯁꯦꯗꯦꯇꯤꯚ-ꯍꯤꯄꯅꯣꯇꯤꯛ ꯗ꯭ꯔꯒꯁꯤꯡ (ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯕꯦꯟꯖꯣꯗꯤꯌꯥꯖꯦꯄꯤꯅꯁꯤꯡ, ꯕꯥꯔꯕꯤꯇꯨꯔꯦꯠꯁꯤꯡ)ꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯁꯤꯖꯤꯟꯅꯗꯕꯅꯥ ꯃꯔꯝ ꯑꯣꯏꯗꯨꯅꯥ CNS ꯌꯥꯝꯅꯥ ꯁꯣꯀꯍꯟꯗꯅꯕꯥ ꯁꯤꯖꯤꯟꯅꯔꯣꯏꯗꯕꯅꯤ꯫

ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥ ꯒꯦꯁ꯭ꯠꯔꯣꯏꯟꯇꯦꯁ꯭ꯇꯥꯏꯅꯦꯂꯒꯤ ꯑꯁꯣꯛ-ꯑꯄꯟ (ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯅꯣꯡꯃꯩ ꯀꯥꯞꯄꯥ, ꯈꯣꯡ ꯍꯥꯝꯕꯥ) ꯊꯣꯀꯄꯥ ꯌꯥꯏ; ꯏꯐꯦꯛꯇꯁꯤꯡ ꯍꯟꯊꯍꯟꯅꯕꯥ ꯆꯥꯅꯕꯥ ꯆꯤꯟꯖꯥꯛꯀꯥ ꯂꯣꯌꯅꯅꯥ ꯂꯧꯅꯕꯥ ꯔꯤꯀꯃꯦꯟꯗ ꯇꯧꯈꯤ꯫